AcquisitionOfNorthernBiologics
Boehringer Ingelheim Acquires Northern Biologics ’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio Acquisition provides assets targeting the tumor stroma and myeloid cellsThese new programs targeting the tumor microenvironment are the latest in a series of strategic acquisitions and collaborations that strengthen Boehringer Ingelheim ’s position in cancer immunology, with leading assets and robust capabilities in cancer vaccines, oncolytic viruses, T-cell engagers and myeloid cell modulators Acquisition of Versant-built company based in Toronto ’s MaRS Discovery District
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Mergers and Aquisitions | Research | Vaccines